Bartonella henselae (Positive IgG Control Serum)

  • Applications
    • IF
  • Code # BHG-1620
  • Size 0.5 mL
  • Price Call for Price
Specifications
  • Application:
    IF
  • Components:
    Bartonella henselae Positive Control Serum
  • Description:

    Vial containing 0.5 ml Bartonella henselae positive IgG human control serum with protein stabilizer and 0.005% thimerosal. Stable at 2-8°C until labeled expiration date.When used undiluted, as provided, specific fluorescent intensity of 3+ or greater should be seen. Optionally, the positive control can be titered to endpoint. If titered, the control should be serially diluted in PBS. When the control has been tested for the endpoint titer by MBL-Bion, an endpoint titer is printed on the positive control vial. Due to variations within each laboratory (fluorescent microscopy, etc.) each laboratory should establish its own mean titer for each lot of positive control (generally + one dilution from stated endpoint).

    For Research Use Only. 

  • Product Type:
    Control Serum
  • Research Area:
    Infectious Disease
  • Short Description:
    For Research Use Only. Not for use in diagnostic procedure.
  • Size:
    0.5 mL
References
  1. Laboratory Diagnosis of Viral Infections, Lennette, E.H. (ed), Dekker, New York, 1985.
  2. Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections, SixthEdition, Schmidt, N.J. and R.W. Emmons (Eds.), A.P.H.A., Washington, D.C., 1989.
  3. Weller, T.H., A.H. Coons, Fluorescent Antibody Studies with Agents of Varicella and Herpes Zoster Propagated In Vitro, Proc. Soc. Exp. Biol. Med., 86:789-794, 1954.
  4. Riggs, J.L., R.J. Siewald, J.H. Burckhalter, C.M. Downs, T.G. Metcalf, Isothiocyanate Compounds as Fluorescent Labeling Agents for Immune Serum, Am. J. Pathol. 34:1081-1097, 1958.
  5. Goldman, M.: Fluorescent Antibody Methods. New York, Academic Press, 1968.
  6. Kawamura, A. Jr.: Fluorescent Antibody Techniques and Their Application. Baltimore, University Park Press, 1969.
  7. Nairn, R.C.: Fluorescent Protein Tracing, Baltimore, Williams and Wilkins, 3rd Ed., 1969.
  8. Johnson, R.B., and R. Libby, Separation of Immunoglobulin M (IgM) Essentially Free of IgG From Serum in Systems Requiring Assay of IgM-Type Antibodies Without Interference From Rheumatoid Factor, J. Clin. Micro. 12:451-454, 1980.
  9. Gispen, R., J. Nagel, B. Brand-Saathof, S. DeGraff, Immunofluorescence Test for IgM Rubella Antibodies in Whole Serum After Absorption with Specific Anti-gamma Fc, Clin. Exp. Immunol., 22:431-437, 1975.
  10. Joassin, L., M. Reginster, Elimination of Nonspecific Cytomegalovirus Immunoglobulin M Activities in the Enzyme-Linked Immunosorbent Assay by Using Antihuman Immunoglobulin G, J. Clin. Microbiol. 23:576-581, 1986.
  11. Lyerla, H.C., F.T. Forrester, The Immunofluorescence (IF) Test, in: Immunofluorescence Methods in Virology, USDHHS, Georgia, 71-81, 1979.
  12. Keller, R., R. Psitchel, J.N. Goldman et al., An IgG-Fc Receptor Induced in Cytomegalovirus-Infected Human Fibroblasts, J. Immuno., 116:772-777, 1976.
  13. Westmoreland, D., J.F. Watkins, The IgG Receptor Induced by Herpes Simplex Virus: Studies Using Radioiodinated IgG, J. Gen. Virol., 24:167-178, 1974.
  14. Holborow, E.J., D.M. Weir, G.D. Johnson, A Serum Factor in Lupus Erythematosus With Affinity for Tissue Nuclei, Br. Med. J., 11:732-734, 1957.
  15. Berg, P.A., I. Roitt, D. Doniach, H.M. Cooper, Mitochondrial Antibodies in Primary Biliary Cirrhosis, Immunol. 17:281-293, 1969.
  16. Chernesky, M.A., C.G. Ray, T.F. Smith, Laboratory Diagnosis of Viral Infections, Cumitech 15, ASM, Washington, D.C., March 1982.
  17. Schmidt, N.J., Update on Class-specific Viral Antibody Assays, Clinical Immunology Newsletter, 5: 81-85, June, 1984.18.
  18. Gardner, P.S., J. McQuillin, Rapid Virus Diagnosis: Application of Immunofluorescence, In: Detection of Virus Specific IgM by Immunofluorescence, Butterworth, Boston,259-287, 1980.
  19. Data on file, MBL Bion, Des Plaines, IL.